Skip to content

Chart Industries GTLS Biomedical — D&A

Discontinued — last reported Q4 '17

Similar metrics at other companies

Baxter International logo
BAXMedical Products & Therapies — Depreciation
$51M+4.1%
TEC
TECHOperating Segments — D&A
$10.17M+15.8%
IR
IRMedical — D&A
$5.63M-4.3%
Baxter International logo
BAXHealthcare Systems & Technologies — Depreciation
$24M-11.1%
Fortive logo
FTVAdvanced Healthcare Solutions — Depreciation, Depletion and Amortization
$50.8M+2.6%
International Flavors & Fragrances logo
IFFHealth & Biosciences — D&A
$93.5M+3.0%

Other financials

Income statement

See full
Revenue$884.8M-11.7%
Gross profit$251.4M-26.0%
Operating income$52.6M-65.5%
Net income-$17.1M-135%
EPS (diluted)-$0.36-138%

Balance sheet

See full
Cash & equivalents$269.4M-9.6%
Total debt$3.9B+1.9%
Total equity$3.2B+5.3%
Total assets$9.7B+4.1%

Cash flow

See full
Operating cash flow-$248.0M-313%
CapEx$24.8M+23.4%
Free cash flow-$272.8M-241%

Valuation

See full
Market cap$9.96B+50.0%
Enterprise value$13.59B+33.6%
P/S2.4×+0.8×

Profitability

See full
Gross margin32.5%-1.3pp
Operating margin6.2%-10.1pp
Net margin-0.6%-6.7pp
FCF margin0.2%-10.3pp

Returns & leverage

See full
Return on equity-0.8%-9.8pp
Debt / equity1.2×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Chart Industries in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Chart Industries’s 10-K, filed February 22, 2018, on SEC EDGAR. View the filing →

Questions, answered.

What does biomedical — D&A mean?
The non-cash cost of using up physical and intangible assets in the Biomedical segment.
How do you interpret biomedical — D&A?
High levels relative to revenue may indicate a capital-intensive segment or significant recent acquisition-related intangible amortization.
How does biomedical — D&A compare across companies?
Standard operating expense disclosure for manufacturing and technology segments.